Puchtler v. Barclays PLC, 1:24-cv-01872

Background

Barclays Bank PLC issued the VXX ETN (iPath S&P 500 VIX Short-Term Future) to give investors exposure to VIX futures; Barclays Bank and parent Barclays PLC (BPLC) sponsored and sold VXX off shelf registration statements.
Barclays lost Well-Known Seasoned Issuer (WKSI) status in 2017, converted to non‑WKSI shelf registrations (2018, 2019) with finite issuance capacity it had to monitor.
Beginning June 2019 through 2021, Barclays failed to track issuances and sold billions of dollars of securities in excess of registered shelf limits; the deficiency was discovered by Barclays in March 2022.
On March 14, 2022 Barclays announced an immediate suspension of further VXX issuances/sales, citing insufficient issuance capacity; the market reacted with a severe short squeeze and dramatic price dislocation in VXX.
The SEC later found material weaknesses and over‑issuances (approximately $17.7 billion in excess), required remedial reforms and assessed civil penalties; Plaintiff (a VXX short seller) sued under Section 10(b)/Rule 10b‑5 and Section 20(a), alleging misstatements about internal controls and that VXX notes were issuable only in registered form.
The district court granted defendants’ motion to dismiss with prejudice, holding Plaintiffs failed to plead actionable misstatements (as to controls), scienter, and loss causation; dismissal of control‑person claims followed from failure to plead a primary violation.

Issues

Issue	Plaintiff's Argument	Defendant's Argument	Held
Material misrepresentation/omission re: internal controls	Barclays’ public filings and SOX certifications represented strong, effective controls while Barclays had no system to track issuances, so statements were materially false/omitted facts	Statements were generic, aspirational or group‑wide and not specifically about ETN issuance controls; therefore nonactionable puffery	Court: statements about internal controls were too general to be actionable (non‑specific “milquetoast” statements)
Material misrepresentation re: “issuable only in registered form”	Registration statement language ("issuable only in registered form") was misleading once Barclays began issuing unregistered securities and thus required update/correction	Statement was true when made (no contemporaneous unregistered issuances); no duty to correct until a statement becomes false or misleading	Court: statement was not false when made; only potentially misleading after unregistered issuances—but scienter and causation defects remain fatal
Scienter (intent/recklessness)	High‑level executives, SOX certifications, loss of WKSI status, size/ease of discovery, and board clawbacks support an inference of conscious recklessness	No motive alleged; executives had no economic incentive to conceal over‑issuance; plausible nonfraudulent inferences (negligence, mismanagement, remedial disclosure) are stronger	Court: scienter inadequately pled—allegations do not yield a cogent, strong inference of intent to deceive; dismissal on scienter grounds granted
Loss causation	March 14, 2022 suspension constructively disclosed the concealed risk (lack of issuance controls/unregistered issuances) and thus caused the short squeeze losses	Suspension exercised a contractual right to suspend issuances; plaintiffs would have suffered same losses even if earlier disclosures had been truthful—no causal link to misstatements	Court: loss causation not alleged—exercise of reserved contractual right (suspension) and market reaction, not revelation of a misrepresentation, caused the loss; dismissal independent on this basis

Key Cases Cited

ATSI Commc’ns, Inc. v. Shaar Fund, Ltd., 493 F.3d 87 (2d Cir.) (documents incorporated by reference standard)
Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (U.S.) (standard for opinion statements and materiality)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (U.S.) (comparative-test for pleading scienter)
Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (U.S.) (duty of disclosure; falsity in context)
In re Vivendi, S.A. Sec. Litig., 838 F.3d 223 (2d Cir.) (loss causation: corrective disclosure vs. materialization of risk)
Lentell v. Merrill Lynch & Co., 396 F.3d 161 (2d Cir.) (loss‑causation and concealed‑risk framework)
Fershtman v. Schectman, 450 F.2d 1357 (2d Cir.) (reserved contractual rights and causation)
Kalnit v. Eichler, 264 F.3d 131 (2d Cir.) (scienter standards for recklessness)
Carpenters Pension Tr. Fund of St. Louis v. Barclays PLC, 750 F.3d 227 (2d Cir.) (general statements about controls not actionable when not tied to specific practice)
Dura Pharmaceuticals, Inc. v. Broudo, 544 U.S. 336 (U.S.) (securities loss causation principles)